Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
GMP Human Flt-3 Ligand Protein, 50µg  

GMP Human Flt-3 Ligand Protein, 50µg

GMP Human Flt-3 Ligand Protein, AA Thr 27 - Pro 185, expressed from human 293 cells (HEK293), (Bioactivity and Stability tested)

Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory, FDA DMF filed

More details

GMP-FLLH28-50

Availability: within 7 days

767,00 €

Background
FMS-like tyrosine kinase 3 ligand (Flt-3 Ligand) is also known as FL, Flt3L and FLT3LG, is an α-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages. FLT3LG is expressed as a noncovalentlylinked dimer by T cells and bone marrow and thymic fibroblasts. Each 36 kDa chain carries approximately 12 kDa of N- and O- linked carbohydrates. FLT3LG is structurally homologous to stem cell factor (SCF) and colony stimulating facor 1 (CSF-1). FLT3LG acts as a growth factor that increases the number of immune cells by activating the hematopoietic progenitors. It also induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3LG induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation. FLT3LG cooperates with IL2, IL6, IL7, and IL15 to induce NK cell development and with IL3, IL7 and IL11 to induce terminal B cell maturation. Animal studies also show FLT3LG to reduce the severity of experimentally induced allergic inflammation. FLT3LG is crucial for steady-state pDC and cDC development. A lack of FLT3L results in low levels of DCs.

Features
- Designed under ISO 9001:2015 and ISO 13485:2016
- Manufactured and QC tested under a GMP compliance factory
- FDA DMF filed
- Animal-Free materials
- Batch-to-batch consistency
- Stringent quality control tests
- No animal derived peptone and lactose used in production process

Source
GMP Human Flt-3 Ligand Protein(GMP-FLLH28) is expressed from human 293 cells (HEK293). It contains AA Thr 27 - Pro 185 (Accession # P49771-1 ).Predicted N-terminus: Thr 27

 

Molecular Characterization
This protein carries no "tag". The protein has a calculated MW of 18.0 kDa. The protein migrates as 24 kDa & 27 kDa±3 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 10 EU per mg by the LAL method.

Host Cell Protein
<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA
<0.02 ng/μg of protein tested by DNA Fluorescent Staining method.

Sterility
The sterility testing was performed by membrane filtration method described in CP<1101>, USP<71> and Eur. Ph. 2.6.1.

Mycoplasma
Negative.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
Shipping at ambient temperature. Upon receipt, store it immediately at -20°C or lower for long term storage.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 5 years in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) In, Park, Shin et al., "Identification of dendritic cell precursor from the CD11c+ cells expressing high levels of MHC class II molecules in the culture of bone marrow with FLT3 ligand", Front Immunol (2023) 14, 1179981
(2) Nagy, Leyrer-Jackson, Hood et al., "Effects of repeated binge intake of the pyrovalerone cathinone derivative 3,4-methylenedioxypyrovalerone on prefrontal cytokine levels in rats - a preliminary study", Front Behav Neurosci (2023) 17, 1275968
(3) D'Anniballe, Huang, Lueck et al., "Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model", J Immunother (2023) 46 (9), 333-340